Antibiotic-tolerant persister bacteria involve frequent treatment failures, relapsing infections and the need 24 for extended antibiotic treatment. Taking persisters into account in susceptibility assays is thus an essential 25 success factor in antibacterial drug discovery. The virulence of the obligate intracellular bacterium 26
Background

53
In the course of evolution, bacteria have developed various means for protecting themselves from 54 unfavorable conditions. Described as a reversible dormant phenotype, persistence has been acknowledged 55 as one major survival strategy of bacteria 1 . Bacterial persistence is considered major cause of antibiotic 56 treatment failures and relapsing infections and it also contributes to the rise of antibiotic resistance 2 . 57
To date, a variety of anti-persister molecules have been described against both gram-positive and gram-85 negative human pathogens, major strategies involving direct eradication of the metabolically quiescent 86 cells by eg. Membrane-active compounds, bacterial resuscitation by boosting energy metabolism and 87 application of combination therapies 2 . According to current consensus, taking persister bacteria into 88 account is a critical success factor in antibacterial drug discovery and this paradigm shift has brought 89 stationary phase cultures, bacterial biofilms and other persister-enriched culture systems as essential tools 90 in this respect. Despite such progress, susceptibility testing and antibacterial discovery platforms for 91 intracellular bacteria still mostly rely on conventional methodology and models on actively replicating 92 bacteria. Regarding C. pneumoniae, only a few membrane-active agents capable of affecting EB infectivity 93 independent of metabolic activity have been described 19, 20 and to date, no agents capable of affecting the 94 persistent intracellular forms of the bacterium have been described. Furthermore, current standard 95 methods for antichlamydial susceptibility testing are based solely on permissive epithelial cells and involve 96 the suppression of host cell responses by cycloheximide treatment 21, 22 . 97 To establish an antichlamydial susceptibility assay allowing the simultaneous analysis of actively growing 98 and persistent bacteria, we studied C. pneumoniae infection in THP-1 macrophages. The model was found 99 to harbor a mixed infection, involving simultaneously present populations of replicating and persister 100 bacteria and its potential in the discovery of antichlamydial agents targeting also persistent bacteria was 101 demonstrated by the identification of schisandrin and schisandrin C, two dibenzocyclooctadiene lignans 102 THP-1 cells (ATCC TIB-202) were maintained in RPMI 1640 Dutch edition medium (Gibco, Invitrogen, 115 Thermo Fisher Scientific, Massachusetts, USA) supplemented with 10 % FBS (BioWhittaker, Lonza, Basel, 116 Switzerland), 2 mM L-glutamine (BioWhittaker, Lonza, Basel, Switzerland), 0.05 mM merkaptoethanol 117 (Gibco, Invitrogen, Thermo Fisher) and 20 g/ml gentamicin (Sigma-Aldrich, St. Louis, MO, USA). For 118 differentiation into macrophage-like cells, THP-1 cells were incubated for 48 -72 h with 0.16 g/ml 119 phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich, St. Louis, MO, USA) . Human HL cells 23 were 120 maintained in RPMI 1640 (BioWhittaker, Lonza, Basel, Switzerland) The EBs were harvested from infected THP-1 macrophages at various time points (72 -144 h) post 151 infection by collecting the culture supernatants, centrifuging them at 21 000 rpm for 1 h in 4 C and 152 resuspending the pellets with 0.2 ml of fresh cold media. Monolayer cells from the same samples were 153 scraped to 0.2 ml of fresh cold media. All samples were stored in -80 C. 154 The bacterial progeny in the samples was quantified by inoculating them on HL monolayers with CHX. 155 After infection, fresh medium with CHX was added and cells were incubated for 70 h. Then, cells were 156 fixed and stained with a genus-specific anti-LPS antibody (Pathfinder, California, USA). 157 Chlamydial titers were determined based on the inclusion counts observed with fluorescence 158 microscope. 159 160 Intracellular ROS detection assay 161 THP-1 macrophages in 96-well plate (6 x 10 4 cells/well) were subjected to an infection by C. pneumoniae, 162 treatment with the schisandrin lignans or a combination of these two, using a culture medium without 163 merkaptoethanol. In experiments with 1 -4 h exposure, the cells were preloaded with 20 μM DCFH-DA 164 (Sigma-Aldrich, St. Louis, MO, USA) for 30 min and washed with PBS prior to lignan administration. After 24 165 -72 h exposures, cells were washed once with PBS, loaded with DCFH-DA for 30 min, washed with PBS and 166 incubated for further 3 hours. After that, fluorescence was recorded at 503/523 nm with Varioskan Lux 167 plate reader. 168 169
Glutathione quantification assay 170
The intracellular GSH levels of THP-1 macrophages after C. pneumoniae infection, lignan treatment or 171 combination of these two were determined using enzymatic recycling method described previously by 172
Rahman et al 26 . 173 For data normalization, total protein concentration determination of the cell lysates was performed with acetone was added. Sample was mixed and incubated 1 h at -20 °C, centrifuged at 15000g and supernatant 176 was discarded. Pellet was resuspended to 100 mM 7.5) Despite the common use of THP-1 cells as infection hosts in studies on C. pneumoniae biology, no 187 comprehensive data on C. pneumoniae replication or infection kinetics in these cells have been available. 188
To evaluate the usefulness of this cell line for establishing a model for chlamydial persistence, the growth 189 kinetics of C. pneumoniae in both monocytic and PMA-differentiated, macrophage-like, THP-1 cells was 190 followed with qPCR. For comparison, epithelial HL cells hosting an active C. pneumoniae infection were 191 included in the study. 192
Consistent with earlier studies reporting active and efficient replication of C. pneumoniae in HL cells 27 , our 193 data with HL cells demonstrate a continuous increase in the number of chlamydial genome equivalents (GE) 194 detectable since 32 h post infection ( Fig. 1A ). As expected, treatment with 20 nM azithromycin resulted in 195 99 % reduction of bacterial genome copy number in these cells. 196
In monocytic THP-1 cells, the C. pneumoniae GE numbers decreased drastically shortly after infection and 197 after 8 h, stayed in a low yet detectable level throughout the observation period ( Fig. 1B) . Azithromycin (20 198 nM) had no detectable effect on the chlamydial genome copy numbers. 199
In contrast to monocytic cells, the GE numbers in infected THP-1 macrophages stayed in constant level until 200 32 h post infection and increased thereafter throughout the observation time (Fig. 1C ). However, C. 201 pneumoniae replication in THP-1 macrophages was less efficient than in HL cells since the genome copy 202 numbers in the macrophages were approximately 20-fold lower than in HL cells at 72 h post infection. 203
Treatment with 20 nM azithromycin resulted in only 73 % reduction of GE numbers in THP-1 macrophages. 204
As the qPCR data indicated the presence of actively dividing population of bacterial cells in THP-1 206 macrophages, we next evaluated whether C. pneumoniae is able to establish a productive infection yielding 207 new infectious progeny in these cells. 208
Within its productive life cycle, C. pneumoniae infectious progeny production occurs typically 48 -72 h post 209 infection, involving differentiation of the newly formed bacterial cells into EBs that leave the host cell to 210 infect neighboring cells. For detecting the production of infectious EB progenies in THP-1 macrophages, 211 subculturing of infected THP-1 cell lysates and culture medium supernatants in HL cells was used. 212
In these experiments, production of C. pneumoniae EBs capable of infecting HL cells was detected in all 213 THP-1 cell lysates and supernatants collected from 72 to 144 h post infection (Table 1) , indicating a 214 continuous, asynchronous production of infectious progeny. In general, significantly higher quantities of IFU 215 were observed in cell lysates than in supernatant samples. A duplication in IFU amounts in supernatants 216 and triplication in cell lysates was observed from 72 to 144 h post infection. 217
Based on these data, it was evident that THP-1 macrophages can harbor a productive C. pneumoniae 218 infection. However, the limited effectiveness of azithromycin in inhibiting C. pneumoniae growth indicates 219 that the infection in this cell population is refractory to this macrolide antibiotic commonly used as a golden 220 standard for treating chlamydial infections and highlights the importance of characterizing antichlamydial 221 compounds also in macrophage-like cells. 222 223
Schisandrin lignans as modulators of C. pneumoniae infection 224
We have recently identified the antichlamydial activity of dibenzocyclooctadiene lignans isolated from a 225 medicinal plant Schisandra chinensis against the actively replicating bacteria in respiratory epithelial cells 28, 226 29 . Within the validation process on the current assay, three of these lignans, schisandrin, schisandrin B and 227 schisandrin C were evaluated for their efficacy against C. pneumoniae in the THP-1 macrophage model at 228
concentrations determined based on cell viability assays ( Supplementary Tables 1 and 2) . superior to all other samples assayed for C. pneumoniae genome number reduction and showed a 238 statistically significant difference to azithromycin in this respect, with 95% reduction in bacterial genome 239 numbers at 72 h and 99 % reduction at 144 h. 240
The effect of the schisandrin lignans on C. pneumoniae infectious progeny production in THP-1 241 macrophages was also evaluated. As shown in Table 2 , schisandrin B and schisandrin C decreased infectious 242 progeny production in a statistically significant manner at 72 and 144 h. In schisandrin C treated samples 243 (25 μM or 50 μM), not any characteristical inclusions were detected, only some small irregular inclusion-like 244 structures were observed in HL monolayers inoculated with the cell lysates and none in those inoculated 245 with supernatant samples. At 50 μM, schisandrin did not have effect on infectious EB production, neither in 246 cell lysates nor in supernatant samples. In contrast, at 25 μM schisandrin treatment resulted in a 247 statistically significant increase in infectious EB quantities detected in THP-1 cell lysates at 72 h post 248 infection. 249
250
Role of cellular redox status in the effects of schisandrin lignans on C. pneumoniae infection 251
As key players in innate immunity, macrophages respond to microbes and other danger signals by 252 generating effector molecules such as reactive oxygen species (ROS) and nitric oxide (NO) intended to kill 253 the pathogen 30 . As the dibenzocyclooctadiene lignans are known for their redox activities and changes in 254 cellular redox status have also been linked to bacterial persistence, we extended the study on differential 255 effects of schisandrin and schisandrin C on C. pneumoniae infection by addressing changes in cellular redox 256 status. As shown in Fig. 3A , both MOI1 and MOI5 C. pneumoniae infections elevated the ROS production of 257 the infected macrophages statistically significantly at 48 h post infection. After 72 h infection ROS levels 258 were elevated in MOI5-infected samples. As also total cellular ATP levels were elevated in the infected 259 samples (supplementary fig. 1 ) but no increase in NADPH oxidase activity was observed (data not shown), 260 this may reflect the manipulation of host cell mitochondrial function in a manner similar to a related 261 pathogen C. trachomatis 31 . While NADPH oxidase is considered the major source of ROS in stimulated 262 macrophages in general, previous studies have proposed that mitochondrial ROS production also takes part 263 in macrophage responses to bacterial invaders 32 . In macrophages, the mitochondrial ROS have been 264 reported to actually contribute to chlamydial survival via mechanisms involving NLRP3 inflammasome 265 activation 33, 34 . basal ROS levels were observed after 4 -48 h exposure, but after 72 h schisandrin and schisandrin C 269 elevated ROS levels at both 25 μM and 50 μM concentration (Fig. 3B ). The concomitant administration of 270 schisandrin and schisandrin C with MOI5 C. pneumoniae infection did not change the detected ROS levels 271 compared to a vehicle-treated control infection (Fig. 3C) . 272
Earlier work on anti-persister agents has indicated that promotion of oxidative stress by increased rOS 273 production eradicates persister bacteria and enhances bacterial killing by conventional antibiotics 35, 36 . 274 Despite the impact of the lignans on macrophage basal rOS levels, ROS promotion is not likely the primary 275 mode of action of the compounds against C. pneumoniae, as the infection-induced ROS levels show no 276 difference between treated and non-treated cells. Furthermore, similar impact on basal ROS levels was 277 observed for schisandrin and schisandrin C despite their opposite effects on C. pneumoniae progeny yields 278 (Table 2) . 279
The impact of C. pneumoniae infection and schisandrin lignans on redox status of THP-1 macrophages was 280 further studied with determining cellular GSH concentrations after infection, lignan treatment, or the 281 combination of these two. As shown in Fig Previous work has highlighted the role of NO and inducible nitric oxide synthase (iNOS) as a trigger for 290 chlamydial persistence in murine RAW264.7 macrophages 17, 37 . NO production in in PBMCs and 291 macrophages involves, however, remarkable inter-species differences 40, 41 and based on data published by 292 us and other research groups, the human THP-1 cell line produces NO neither in its monocytic nor 293 macrophage like phenotype [42] [43] [44] . The lack of iNOS induction after chlamydial trigger can be speculated to 294 enable the productive C. pneumoniae infection in THP-1 macrophages, yet more comprehensive picture on 295 host cell redox status is necessary in order to draw conclusions in this respect. 296
297
The medicinal plant-derived schisandrin lignans have recently been reported to harbour pharmacological 298 activities, such as neuro-and cytoprotective as well as anti-inflammatory properties 45 . A key mechanism 299 mediating these activities is considered to be the lignans' impact on cellular redox status. The promotion of redox activities is linked to their ability to modulate mitochondrial functions 46, 47 . In addition, our previous 301 studies in monocytic THP-1 cells showed that the lignans affect cellular glutathione metabolism by causing 302 a decrease in total GSH pools 42 . Similar to monocytic THP-1 cells, THP-1 macrophages exhibit remarkably 303 lowered GSH pools after lignan treatment (Fig. 4B) , and a drastic decrease in GSH levels was also observed 304 in C. pneumoniae -infected THP-1 macrophages after lignan exposure (fig. 4C ). The relevance of GSH 305 depletion in the lignans' activities on C. pneumoniae was confirmed by supplementing the infected cultures 306 with GSH ethyl ester. While administration of this cell-permeable GSH derivative alone increased EB yields 307 by approximately 40 %, supplementation of schisandrin-treated infections yielded infectious progeny levels 308 similar or lower than those in the infection control, indicating that the GSH supplementation eliminates the 309 elevating effect of the 25 μM schisandrin on bacterial progeny production. 310
311
The cellular GSH balance may affect intracellular bacteria by a variety of mechanisms. GSH has been found 312 to act as a major cysteine source of intracellular bacteria 48 and it has been reported to indirectly affect 313 chlamydial energy supply by increasing cell wall permeability 49 . GSH depletion is also known to induce K + 314 efflux 50 which, in turn, can promote the chlamydial replication via the induction of NLRP3 inflammasome in 315 the host cells 33, 51 . On the other hand, GSH and its metabolites are directly toxic to some intracellular 316 bacteria 52 and the GSH-dependent changes in cellular redox status may detrimentally affect C. pneumoniae 317 survival, as suggested in murine models 37 . Interestingly, GSH is also known to induce virulence gene 318 expression of Listeria monocytogenes 53 , implying that it may serve as an indicator of the local 319 environment, directing virulence gene expression of intracellular bacteria. To date, processes linked to the 320 ability of Chlamydia spp. Bacteria to sense their microenvironment have remained poorly understood, and 321 the potential role of GSH in chlamydial adaptation and balance between active and persistent phenotype 322 warrants further investigation. 323
Despite their similar effects on cellular ROS and GSH levels, schisandrin and schisandrin C show differential 324 activity on the C. pneumoniae infection in THP-1 macrophages. This may reflect two separate aspects of 325 their biological activities: a redox-dependent phenotypic switch by C. pneumoniae from persister to active 326 replication and a dual mode of antichlamydial action by schisandrin C. While schisandrin C exhibits 327 chlamydiocidal activity in the acute infection model, schisandrin does not affect actively dividing bacteria at 328 25 μM concentration 29 . Based on these observations, we propose that depleting cellular GSH stimulates 329 chlamydial growth, and persistent infection is converted to active state. In the case of schisandrin this is 330 seen as the promotion of infectious progeny formation, whereas schisandrin C acts as a multimodal 331 antibacterial agent yielding a potent eradication of macrophages by killing the bacteria it is switching 332 towards active replication.
To date, only a few drug-like molecules have been described as phenotypic switchers reverting persister 334 bacteria from dormancy to active growth 2, 54, 55 and to our knowledge, the schisandrin lignans represent the 335 first phenotypic switchers described to be active on intracellular bacteria. Based on rodent bioavailability 336 studies, micromolar plasma concentrations of the lignans can be achieved after a single oral dose 56 , 337 indicating the potential of the lignans as leads for orally administered drugs. Furthermore, our in vitro cell 338 viability data (Supplementary information, 29, 42 and the numerous in vivo studies on these compounds 45 339 indicate the lack of acute or subacute toxicity of the lignans. 340
To conclude, the constant increase of detected number of bacterial copy numbers and infectious progeny 341 in our studies indicates that C. pneumoniae is able to establish a productive infection in THP-1 monocyte-342 schisandrin B 10µM 0.10 ± 0.03** 0.01 ± 0.00*** 0.28 ± 0.18 0.04 ± 0.01*** schisandrin C 25µM 0.00 ± 0.00** 0.00 ± 0.00*** 0.00 ± 0.00** 0.00 ± 0.00*** schisandrin C 50µM 0.00 ± 0.00** 0.00 ± 0.00*** 0.00 ± 0.00** 0.00 ± 0.00*** azithromycin 100nM 0.18 ± 0.20** 0.05 ± 0.03*** 0.30 ± 0.21 0.00 ± 0.00*** infection (IFU/ml) 49 700 ± 16 000 140 200 ± 22 800 5 400 ± 2 100 12 300 ± 700 THP-1 cells were exposed to schisandra lignans for 4 to 72 h. (C) Cells were infected with MOI5 and exposed 569 to schisandra lignans for 48 and 72 h. Total basal GSH concentrations were determined and normalized to 570 total protein concentration of the sample. Data are shown as a ratio of 0.25 % DMSO control and shown as 571 mean ± SEM. Statistical significance is presented as marks of P values: < 0.05: *; < 0.01: **; < 0.001: ***. 572 N=4. Abbreviations: Glutathione, GSH; Multiplicity of infection, MOI; phorbol-12-myristate-13-acetate, 573
